Zekri Wael, Alfaar Ahmad Samir, Yehia Dina, Elshafie Maged M, Zaghloul Mohamed Saad, El-Kinaai Naglaa, Taha Hala, Refaat Amal, Younes Alaa A
Pediatric Oncology Department, Children's Cancer Hospital Egypt, Cairo, Egypt.
Pediatr Blood Cancer. 2014 Dec;61(12):2185-90. doi: 10.1002/pbc.25192. Epub 2014 Aug 31.
Clear cell sarcoma of the kidney (CCSK) is a rare and aggressive tumor accounting for 5% of pediatric renal tumors with an incidence of 20 patients per year in the USA. It is bone metastasizing with poor prognosis. Our aim was to show characteristics of patients in relation to improved outcome in one of the developing countries.
We included all patients diagnosed as CCSK in the period between July 2007 and March 2012 at Children's Cancer Hospital, Egypt. Patients' demographics, clinical presentation, pathology, and management were reviewed. Follow up was continued until April 2013.
Twenty-five patients were identified in the defined time interval, accounting for 7% all renal tumors diagnosed at the hospital. Mean age was 36 months. Abdominal swelling and hematuria were the most common presentations. Stages I, II, III, IV, and V represented 9 (36%), 3 (12%), 8 (32%), 3 (12%), and 2 (8%), respectively. Twenty-four patients had radical nephrectomy either upfront or after neo-adjuvant chemotherapy. Surgery was followed by adjuvant chemotherapy. Abdominal radiotherapy was given for local stages II and III. Twenty-two patients reached complete remission, while one patient had stationary disease and two patients died due to progression and relapse. Overall survival was 88.5% and event-free survival was 87.8% at 45 months.
Although previous studies indicate poor prognosis of CCSK, our experience shows that those patients can be treated using extensive chemotherapy combined with proper local control.
肾透明细胞肉瘤(CCSK)是一种罕见且侵袭性强的肿瘤,占儿童肾肿瘤的5%,在美国每年发病率为20例患者。它易发生骨转移,预后较差。我们的目的是展示一个发展中国家患者与改善预后相关的特征。
我们纳入了2007年7月至2012年3月期间在埃及儿童癌症医院被诊断为CCSK的所有患者。回顾了患者的人口统计学、临床表现、病理学和治疗情况。随访持续至2013年4月。
在规定的时间间隔内确定了25例患者,占该医院诊断的所有肾肿瘤的7%。平均年龄为36个月。腹部肿胀和血尿是最常见的表现。I、II、III、IV和V期分别占9例(36%)、3例(12%)、8例(32%)、3例(12%)和2例(8%)。24例患者在术前或新辅助化疗后进行了根治性肾切除术。手术后进行辅助化疗。对局部II期和III期患者进行腹部放疗。22例患者达到完全缓解,1例患者病情稳定,2例患者因病情进展和复发死亡。45个月时总生存率为88.5%,无事件生存率为87.8%。
尽管先前的研究表明CCSK预后较差,但我们的经验表明,这些患者可以通过广泛化疗结合适当的局部控制进行治疗。